NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.78 -0.06 (-0.26 %)
(As of 08/19/2018 09:08 AM ET)
Previous Close$22.78
Today's Range$21.90 - $22.83
52-Week Range$9.03 - $24.20
Volume961,445 shs
Average Volume1.43 million shs
Market Capitalization$2.31 billion
P/E Ratio-21.29
Dividend YieldN/A
Beta1.92
Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio3.28
Quick Ratio3.23

Price-To-Earnings

Trailing P/E Ratio-21.29
Forward P/E Ratio-25.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$128.37 million
Price / Sales18.80
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book6.53

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-41.24%
Return on Equity-27.71%
Return on Assets-19.34%

Miscellaneous

Employees215
Outstanding Shares105,960,000
Market Cap$2.31 billion

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. The biotechnology company earned $24.17 million during the quarter, compared to the consensus estimate of $27.58 million. Spectrum Pharmaceuticals had a negative return on equity of 27.71% and a negative net margin of 41.24%. The company's quarterly revenue was down 29.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.11) EPS. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

4 analysts have issued twelve-month target prices for Spectrum Pharmaceuticals' shares. Their predictions range from $25.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $29.00 in the next year. This suggests a possible upside of 27.3% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP & Chief Legal Officer

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

Headlines about SPPI stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media and rumor sentiment score of 0.14 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Spectrum Pharmaceuticals.

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.88%), FMR LLC (5.81%), Renaissance Technologies LLC (3.38%), Dimensional Fund Advisors LP (1.08%), Bank of New York Mellon Corp (1.06%) and Wells Fargo & Company MN (1.04%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, FMR LLC, BNP Paribas Arbitrage SA, Ashford Capital Management Inc., ClariVest Asset Management LLC, Fisher Asset Management LLC and California Public Employees Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, Point72 Asset Management L.P., Macquarie Group Ltd., International Biotechnology Trust PLC, Sio Capital Management LLC, Bank of America Corp DE and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $22.78.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.31 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.